Welcome to LookChem.com Sign In|Join Free

CAS

  • or

670253-38-0

Post Buying Request

670253-38-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

670253-38-0 Usage

General Description

6-Amino-4-chloro-3-pyridinecarbonitrile is a chemical compound with the molecular formula C6H3ClN4. It is a derivative of pyridine and contains an amino group, a chloro group, and a cyano group. 6-AMino-4-chloro-3-pyridinecarbonitrile is commonly used in the synthesis of pharmaceuticals and agrochemicals. It may also be used as an intermediate in organic synthesis. Its properties and uses make it an important building block in the production of various compounds and materials. However, it is important to handle this chemical with care due to its potential hazardous properties.

Check Digit Verification of cas no

The CAS Registry Mumber 670253-38-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,0,2,5 and 3 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 670253-38:
(8*6)+(7*7)+(6*0)+(5*2)+(4*5)+(3*3)+(2*3)+(1*8)=150
150 % 10 = 0
So 670253-38-0 is a valid CAS Registry Number.

670253-38-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-amino-4-chloronicotinonitrile

1.2 Other means of identification

Product number -
Other names 2-amino-4-chloro-5-cyanopyridine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:670253-38-0 SDS

670253-38-0Relevant articles and documents

THERAPEUTIC COMPOUNDS AND METHODS OF USE

-

Paragraph 0732; 0733; 0734, (2021/05/21)

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Barlaam, Bernard,Casella, Robert,Cidado, Justin,Cook, Calum,De Savi, Chris,Dishington, Allan,Donald, Craig S.,Drew, Lisa,Ferguson, Andrew D.,Ferguson, Douglas,Glossop, Steve,Grebe, Tyler,Gu, Chungang,Hande, Sudhir,Hawkins, Janet,Hird, Alexander W.,Holmes, Jane,Horstick, James,Jiang, Yun,Lamb, Michelle L.,McGuire, Thomas M.,Moore, Jane E.,O'Connell, Nichole,Pike, Andy,Pike, Kurt G.,Proia, Theresa,Roberts, Bryan,San Martin, Maryann,Sarkar, Ujjal,Shao, Wenlin,Stead, Darren,Sumner, Neil,Thakur, Kumar,Vasbinder, Melissa M.,Varnes, Jeffrey G.,Wang, Jianyan,Wang, Lei,Wu, Dedong,Wu, Liangwei,Yang, Bin,Yao, Tieguang

supporting information, p. 15564 - 15590 (2021/01/09)

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies.

Novel crystal form product of urea compound, and preparation method thereof

-

Paragraph 0033-0034; 0039, (2020/07/06)

The invention particularly relates to a novel crystal form of a urea compound, and a preparation method thereof. According to the method, an organic solvent crystallization solvent system is adopted,an free alkali and an acid are paired to form ion pairs, crystallization is conducted, and then heat preservation pulping crystallization is conducted within a certain temperature range to obtain thenovel crystal form, wherein the crystal form product is high in water solubility, simple in preparation method, high in yield, stable in property and easy to store, transport and use in the later period. The preparation method provided by the invention is good in process reproducibility, simple to operate and suitable for industrial production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 670253-38-0